Follow
Frederick L. Locke
Frederick L. Locke
Chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy
Verified email at moffitt.org - Homepage
Title
Cited by
Cited by
Year
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ...
New England Journal of Medicine 377 (26), 2531-2544, 2017
46762017
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
DW Lee, BD Santomasso, FL Locke, A Ghobadi, CJ Turtle, JN Brudno, ...
Biology of blood and marrow transplantation 25 (4), 625-638, 2019
21002019
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
SS Neelapu, S Tummala, P Kebriaei, W Wierda, C Gutierrez, FL Locke, ...
Nature reviews Clinical oncology 15 (1), 47-62, 2018
20232018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
FL Locke, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, OO Oluwole, ...
The lancet oncology 20 (1), 31-42, 2019
18312019
KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma
M Wang, J Munoz, A Goy, FL Locke, CA Jacobson, BT Hill, ...
New England journal of medicine 382 (14), 1331-1342, 2020
13192020
Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma
FL Locke, DB Miklos, CA Jacobson, MA Perales, MJ Kersten, OO Oluwole, ...
New England Journal of Medicine 386 (7), 640-654, 2022
7442022
Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma
FL Locke, SS Neelapu, NL Bartlett, T Siddiqi, JC Chavez, CM Hosing, ...
Molecular Therapy 25 (1), 285-295, 2017
6522017
Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium
LJ Nastoupil, MD Jain, L Feng, JY Spiegel, A Ghobadi, Y Lin, S Dahiya, ...
Journal of Clinical Oncology 38 (27), 3119, 2020
5732020
Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology
JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ...
Journal of the National Comprehensive Cancer Network 17 (3), 255-289, 2019
4822019
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
MC Pasquini, ZH Hu, K Curran, T Laetsch, F Locke, R Rouce, ...
Blood advances 4 (21), 5414-5424, 2020
3232020
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
FL Locke, JM Rossi, SS Neelapu, CA Jacobson, DB Miklos, A Ghobadi, ...
Blood advances 4 (19), 4898-4911, 2020
2672020
Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)
RM Alvi, MJ Frigault, MG Fradley, MD Jain, SS Mahmood, M Awadalla, ...
Journal of the American College of Cardiology 74 (25), 3099-3108, 2019
2582019
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma
K Rejeski, A Perez, P Sesques, E Hoster, C Berger, L Jentzsch, ...
Blood, The Journal of the American Society of Hematology 138 (24), 2499-2513, 2021
2062021
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit'ALL'
SS Neelapu, S Tummala, P Kebriaei, W Wierda, FL Locke, Y Lin, N Jain, ...
Nature reviews Clinical oncology 15 (4), 218-218, 2018
1992018
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
MV Maus, S Alexander, MR Bishop, JN Brudno, C Callahan, ML Davila, ...
Journal for immunotherapy of cancer 8 (2), 2020
1762020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
JM Logue, E Zucchetti, CA Bachmeier, GS Krivenko, V Larson, D Ninh, ...
Haematologica 106 (4), 978, 2021
1712021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma
MD Jain, H Zhao, X Wang, R Atkins, M Menges, K Reid, K Spitler, ...
Blood, The Journal of the American Society of Hematology 137 (19), 2621-2633, 2021
1622021
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma
EA Dean, RS Mhaskar, H Lu, MS Mousa, GS Krivenko, A Lazaryan, ...
Blood Advances 4 (14), 3268-3276, 2020
1552020
Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL)
FL Locke, SS Neelapu, NL Bartlett, LJ Lekakis, CA Jacobson, ...
Blood 130, 1547, 2017
1532017
Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience
LJ Nastoupil, MD Jain, JY Spiegel, A Ghobadi, Y Lin, S Dahiya, ...
Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018
1302018
The system can't perform the operation now. Try again later.
Articles 1–20